Last Price$19.1(7.5%)
Market Cap$14.6B
LTM Return on Invested Capital (ROIC)
(3,335.4%)
5Y avg
(1,367.8%)
Biotechnology industry
median
(131.8%)
Stock quality & Intrinsic value
6/10
(1.0%) overvalued
Summit Therapeutics Inc. Return on Invested Capital (ROIC)
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Invested Capital (ROIC) | (395.5%) | (172.3%) | (86.4%) | (60.0%) | (84.0%) | (162.3%) | (281.5%) | (1,038.4%) | (345.5%) | (311.7%) | (376.5%) | (423.0%) | (90.8%) | 88.3% | (309.0%) | (514.0%) | (613.3%) | (41.2%) | (56.5%) | 5.8% |
Overvalued or undervalued?
Check the intrinsic value for SMMT
and see if it's the right time to invest.
Summit Therapeutics Inc. (SMMT) Return on Invested Capital (ROIC) comparison analysis
General
LTM Return on Invested Capital (ROIC)
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Summit Therapeutics Inc.SMMT
(3,335.4%)
N/A
(68.7%)
N/A
Median Peer Set
(9.9%)
18.9%
(41.2%)
12.6%
United Therapeutics CorporationUTHR
65.4%
23.6%
25.7%
41.5%
Novo Nordisk A/SNVO
35.5%
24.9%
142.8%
34.8%
Regeneron Pharmaceuticals, Inc.REGN
25.0%
8.3%
10.4%
31.1%
Royalty Pharma plcRPRX
14.5%
(3.8%)
(43.7%)
37.9%
Alnylam Pharmaceuticals, Inc.ALNY
(7.2%)
23.0%
(38.6%)
(12.4%)
Incyte CorporationINCY
(12.7%)
14.8%
(94.0%)
0.8%
Vertex Pharmaceuticals IncorporatedVRTX
(15.0%)
11.7%
N/A
(4.9%)
BeiGene, Ltd.BGNE
(38.4%)
73.7%
(56.5%)
(35.9%)
argenx SEARGX
(41.3%)
198.6%
(60.5%)
(24.1%)
BioNTech SEBNTX
(41.4%)
(77.4%)
(89.7%)
24.4%
SMMT key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1.7 338.9% | 3.8 119.8% | 12.1 219.9% | 0.5 (96.0%) | 0.5 (1.1%) | 1.9 290.6% | 4.4 138.3% | 4.6 2.5% | 3.6 (21.8%) | 3.7 4.3% | 0.0 (100.0%) | 3.9 0.0% | 46.8 1,114.8% | 74.9 59.9% | 0.8 (98.9%) | 0.9 6.6% | 1.8 110.3% | 0.7 (61.1%) | 0.0 (100.0%) | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.8 | 1.1 | 5.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 2.5 | 2.1 | 15.0 |
% margin | 1.0 56.1% | 2.7 70.6% | 7.0 58.3% | 0.5 97.8% | 0.5 100.0% | 1.9 100.0% | 2.8 63.7% | 4.6 100.0% | 3.6 100.0% | 3.7 100.0% | 0.0 0.0% | 3.9 100.0% | 46.7 99.7% | 74.8 100.0% | 0.6 75.4% | 0.9 100.0% | 1.8 100.0% | (1.8) (257.0%) | (2.1) 0.0% | (15.0) 0.0% |
| Operating Expenses | 6.8 | 18.6 | 53.9 | 27.9 | 15.0 | 8.6 | 11.9 | 13.5 | 20.9 | 31.6 | 44.8 | 45.4 | 70.4 | 63.3 | 53.6 | 53.2 | 88.0 | 64.3 | 87.7 | 211.3 |
| Research & Development Expenses (R&D) | 3.3 | 10.8 | 30.7 | 13.3 | 5.8 | 5.7 | 7.7 | 9.1 | 17.0 | 25.6 | 36.4 | 31.7 | 53.4 | 68.2 | 41.7 | 53.3 | 85.4 | 52.0 | 59.5 | 150.8 |
| Selling, General & Administrative Expenses (SG&A) | 3.2 | 3.5 | 14.6 | 9.1 | 6.6 | 4.1 | 3.7 | 4.4 | 5.1 | 11.1 | 11.3 | 13.8 | 22.1 | 21.5 | 11.9 | 19.2 | 23.6 | 26.7 | 28.2 | 60.5 |
% margin | (5.8) (338.9%) | (16.0) (423.8%) | (46.9) (388.4%) | (34.7) (7,198.9%) | (14.5) (3,047.6%) | (14.5) (777.1%) | (7.6) (170.1%) | (11.5) (252.3%) | (17.4) (487.9%) | (31.3) (844.4%) | (43.7) 0.0% | (41.6) (1,078.7%) | (23.7) (50.7%) | 16.4 21.9% | (54.6) (6,766.4%) | (53.2) (6,185.2%) | (86.2) (4,764.3%) | (72.1) (10,235.6%) | (89.7) 0.0% | 0.3 0.0% |
| Interest Income | 1.9 | 3.2 | 3.1 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.7 | 4.9 | 0.0 | 0.0 | 0.2 | 1.5 | 10.4 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 1.4 | 2.1 | 0.7 | 0.0 | 0.3 | 0.3 | 4.4 | 16.5 | (8.7) |
| Pre-tax Income | (3.9) | (12.8) | (43.9) | (34.2) | (14.7) | (14.4) | (7.5) | (11.5) | (17.3) | (31.2) | (43.7) | (43.0) | (20.1) | 8.8 | (36.3) | (52.9) | (88.6) | (78.8) | (615.9) | (221.3) |
% effective tax rate | (0.5) 12.8% | (1.8) 13.9% | (3.6) 8.3% | (4.6) 13.3% | (0.9) 6.4% | (3.0) 20.7% | (0.8) 10.1% | (0.9) 7.5% | (1.6) 9.1% | (3.2) 10.2% | (6.6) 15.2% | (7.3) 16.9% | (6.9) 34.5% | (4.3) (49.6%) | (5.8) 15.9% | (0.2) 0.4% | (2.5) 2.8% | (4.4) 5.6% | (0.9) 0.2% | 0.0 0.0% |
% margin | (3.4) (199.7%) | (11.0) (292.1%) | (40.3) (334.1%) | (58.4) (12,109.8%) | (13.7) (2,867.2%) | (11.4) (614.7%) | (6.8) (152.6%) | (10.6) (232.9%) | (15.8) (443.1%) | (28.0) (754.9%) | (37.0) 0.0% | (35.7) (927.6%) | (13.1) (28.1%) | 13.1 17.5% | (30.5) (3,779.1%) | (52.7) (6,127.6%) | (86.1) (4,762.1%) | (74.4) (10,561.1%) | (614.9) 0.0% | (221.3) 0.0% |
| EPS | (0.11) | (0.30) | (0.84) | (1.09) | (0.21) | (0.07) | (0.04) | (0.67) | (3.26) | (0.70) | (0.62) | (0.58) | (0.21) | 0.15 | (0.19) | (0.76) | (0.93) | (0.38) | (0.99) | (0.31) |
| Diluted EPS | (0.11) | (0.30) | (0.84) | (1.09) | (0.21) | (0.07) | (0.04) | (0.67) | (3.26) | (0.70) | (0.62) | (0.58) | (0.20) | 0.15 | (0.19) | (0.76) | (0.93) | (0.38) | (0.99) | (0.31) |
% margin | (5.4) (313.6%) | (11.4) (302.4%) | (37.2) (308.4%) | (29.0) (6,010.3%) | (8.5) (1,790.5%) | (13.3) (716.0%) | (7.1) (159.0%) | (8.7) (191.3%) | (17.3) (486.0%) | (20.0) (537.9%) | (30.9) 0.0% | (41.5) (1,075.8%) | (41.9) (89.5%) | 15.5 20.7% | (21.4) (2,657.4%) | (37.1) (4,317.9%) | (62.7) (3,468.0%) | (52.6) (7,472.8%) | 1.0 0.0% | 0.3 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Summit Therapeutics Inc.'s Return on Invested Capital (ROIC)?
As of today, Microsoft Corp's last 12-month Return on Invested Capital (ROIC) is (3,335.4%), based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Return on Invested Capital (ROIC) for Summit Therapeutics Inc. have been (1,789.6%) over the past three years, and (1,436.2%) over the past five years.
2) Is Summit Therapeutics Inc.'s Return on Invested Capital (ROIC) Good?
As of today, Summit Therapeutics Inc.'s Return on Invested Capital (ROIC) is (3,335.4%), which is lower than industry median of (131.8%). It indicates that Summit Therapeutics Inc.'s Return on Invested Capital (ROIC) is Bad.